Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Burlington, Massachusetts 01805


Purpose:

The purpose of this study is to test the effectiveness, safety and side effects of two chemotherapy drugs (gemcitabine and cisplatin) when combined with surgery after chemotherapy for patients with upper urinary tract cancer. The hypothesis is that undergoing chemotherapy prior to surgery will have a beneficial effect on prognosis and may improve overall survival as in patients with bladder cancer, and will allow better tolerance of chemotherapy than if it were given after surgery.


Study summary:

This study will look at improving overall survival of those undergoing nephroureterectomy for upper tract TCC (transitional cell carcinoma, comparing the pathological response of tumors treated with Neoadjuvant Chemotherapy (gemcitabine and cisplatin) before surgery. There have been reported studies of neoadjuvant chemotherapy in the treatment of upper tract TCC, there have been no studies to date that include the chemotherapy agents gemcitabine and cisplatin that are currently indicated in treating TCC of the bladder in the neoadjuvant and adjuvant setting. These agents have been proven to have a better overall safety profile and tolerability allowing more patients to complete their regimens. Secondarily, study will compare disease free overall survival among patients treated with neoadjuvant chemotherapy and surgery versus surgery alone. This study may elucidate the potential benefit of these agents when treating TCC of the upper tracts and may provide a survival advantage in this specific patient population as compared to a historical cohort.


Criteria:

Inclusion Criteria: - ECOG performance status 0-2 - Estimated GFR>60 - High grade TCC on initial biopsy - Clinical stage T1-T3, Nx, Mx based on the AJCC Classification system - TCC confined to the ureter or renal pelvis - Grade II neuropathy or less Exclusion Criteria: - Any other malignancy over the previous five years with a risk of relapse that exceeds 30% - History of previous cystectomy - Evidence of metastatic disease - History of pelvic irradiation or prior chemotherapy


NCT ID:

NCT00696007


Primary Contact:

Principal Investigator
Christopher G. Tretter, M.D.
Lahey Clinic, Inc.


Backup Contact:

N/A


Location Contact:

Burlington, Massachusetts 01805
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.